BC-1901S
BC-1901S is a proteasome-independent NRF2 activator and stabilizer. BC-1901S binds to DCAF1 (E3 ligase subunit) and disrupts NRF2/DCAF1 interaction, and activates NRF2 by inhibiting NRF2 ubiquitination in a KEAP1-independent manner. BC-1901S shows anti-inflammatory effect in a murine model of LPS-induced acute lung injury[1].
Product Specifications
CAS Number
[1358617-36-3]
UNSPSC
12352005
Target
E1/E2/E3 Enzyme; Keap1-Nrf2
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/bc-1901s.html
Purity
99.81
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(C1CCN(CC1)C2=NC(C3=CC(C)=CC=C3)=NC=C2)NC4=CC=C(C(Cl)=C4)F
Molecular Formula
C23H22ClFN4O
Molecular Weight
424.90
References & Citations
[1]Chen Y, et al. A small molecule NRF2 activator BC-1901S ameliorates inflammation through DCAF1/NRF2 axis. Redox Biol. 2020 May;32:101485.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
CD79a (B lymphocyte-specific MB1 Protein, B Cell antigen receptor complex-Associated Protein alpha chain, CD79a Molecule immunoglobulin Associated alpha, Ig-alpha, IGA, IgM-alpha, Immunoglobulin-Associated alpha, Ly54, MB-1 Membrane GlycoProtein, Membrane